Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines

Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines

The course of the COVID-19 pandemic has been critically altered by the availability of vaccines. To assess the risk of COVID-19 in the vaccinated, as compared to the unvaccinated population, as well as the comparative effectiveness of the BBIBP-CorV (Sinopharm), BNT162b2 (Pfizer/BioNTech), Gam-COVID...

Full description

Bibliographic Details
Main Authors:	Zoran Kokić, Predrag Kon, Olgica Djurković-Djaković
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Vaccines
Subjects:	COVID-19 vaccination vaccine effectiveness BBIBP-CorV BNT162b2 Gam-COVID-Vac
Online Access:	https://www.mdpi.com/2076-393X/11/3/544

Similar Items

Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study
by: Vladimir Petrović, et al.
Published: (2022-12-01)

Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report
by: Olivera Lijeskić, et al.
Published: (2021-09-01)

Effectiveness of the first and the second dose of COVID-19 vaccines in Serbia during the first three months of rollout
by: Đorđević Nataša, et al.
Published: (2024-01-01)

Effectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-COV-2: A Serbian cohort study
by: Đorđević Nataša, et al.
Published: (2023-01-01)

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study
by: Soledad González, et al.
Published: (2022-09-01)

Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine
by: Éva Rákóczi, et al.
Published: (2023-02-01)

Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco
by: Yaowen Zhang, et al.
Published: (2022-08-01)

Side Effects and Efficacy of COVID-19 Vaccines among the Egyptian Population
by: Marwa O. Elgendy, et al.
Published: (2022-01-01)

COVID-19 in Latin America: A Snapshot in Time and the Road Ahead
by: Jorge LaRotta, et al.
Published: (2023-01-01)

Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2
by: Enikő Szabó, et al.
Published: (2023-07-01)

Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
by: Chandima Jeewandara, et al.
Published: (2022-06-01)

Variety of Antibody Responses to BNT162b2 and BBIBP-CorV Vaccinations Against COVID-19 Infections in Baghdad and Fallujah, Iraq
by: Mohammed A. Hamad, et al.
Published: (2023-08-01)

Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease
by: Chao Wang, et al.
Published: (2022-06-01)

Comparative Assessment of the Kinetics of Cellular and Humoral Immune Responses to COVID-19 Vaccination in Cancer Patients
by: Lina Souan, et al.
Published: (2023-06-01)

Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants
by: Rima Moghnieh, et al.
Published: (2022-09-01)

Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand
by: Saraiorn Thonginnetra, et al.
Published: (2022-10-01)

Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization
by: Haijun Tang, et al.
Published: (2022-03-01)

COVID-19 Antibody Seroconversion in Cancer Patients: Impact of Therapy Cessation—A Single-Center Study
by: Lina Souan, et al.
Published: (2023-10-01)

A real-world study of BBIBP-CorV vaccine effectiveness in a Sri Lanka rural province
by: Lanka Wijekoon, et al.
Published: (2024-09-01)

Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
by: Jira Chansaenroj, et al.
Published: (2022-07-01)

Studying the effects of booster shots and antibody responses to the SARS-CoV-2 vaccination over time in health personnel
by: Jingjing Wu, et al.
Published: (2023-03-01)

Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers
by: Houda Amellal, et al.
Published: (2023-08-01)

COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates
by: Nihar Ranjan Dash, et al.
Published: (2023-02-01)

Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity
by: Nahad Sedaghat, et al.
Published: (2023-02-01)

IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China
by: Guang Zeng, et al.
Published: (2022-05-01)

The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults
by: Qinjin Wang, et al.
Published: (2022-11-01)

Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort
by: Batool Zamani, et al.
Published: (2023-05-01)

Study of Humoral Immunity against Coronavirus Infection COVID-19 in Vaccinated Individuals with Vaccines Available in the Republic of Belarus (Sputnik V (Gam-COVID-Vac), RF and Sinopharm (BBIBP-CorV), PRC)
by: K. S. Korsak, et al.
Published: (2023-03-01)

Ischemic stroke following COVID-19 vaccination
by: Nooshin Masoudian, et al.
Published: (2023-11-01)

SARS-CoV-2-Specific IgG and IgA response in maternal blood and breastmilk of vaccinated naïve and convalescent lactating participants
by: Yesica Longueira, et al.
Published: (2022-10-01)

Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study
by: Juan C. Gómez de la Torre, et al.
Published: (2022-04-01)

Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population
by: Javeria Aijaz, et al.
Published: (2022-04-01)

Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers
by: Najlaa Assaid, et al.
Published: (2022-03-01)

Side effects and perceptions following Sinopharm COVID-19 vaccination
by: Balsam Qubais Saeed, et al.
Published: (2021-10-01)

Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
by: Kriangkrai Tawinprai, et al.
Published: (2022-05-01)

Clinical characteristics, outcomes, and risk factors of SARS-CoV-2 breakthrough infections among 572 fully vaccinated (BBIBP-CorV) hospitalized patients
by: Yihuang Liu, et al.
Published: (2023-11-01)

Monitoring and active surveillance of adverse events following the booster dose of AZD1222 vaccine in people vaccinated with Sinopharm BBIBP-CorV: a cohort study
by: Shahin Soltani, et al.
Published: (2025-02-01)

Analysis of Antibodies Induced after SARS-CoV-2 Vaccination Using Antigen Coded Bead Array Luminex Technology
by: Zixuan Song, et al.
Published: (2023-02-01)

Constrictive pericarditis following inactivated virus COVID-19 vaccine: a case report with review of the literature
by: Shokoufeh Hajsadeghi, MD, et al.
Published: (2022-10-01)

Characterization of the Intestinal Microbiome in Healthy Adults over Sars-Cov-2 Vaccination
by: Jie Jiao, et al.
Published: (2022-10-01)